| Followers | 23 |
| Posts | 2036 |
| Boards Moderated | 0 |
| Alias Born | 12/06/2017 |
Monday, October 11, 2021 1:25:15 PM
Too bad this is another scam stock... Man when will these scammers stop stealing from the public???? the deal is so under water no body makes money but the ones that do the deal 1.76 today Oct 11th they shorted the deal with the warrants imo
Aditxt Inc. shares were down 30% to $2.14 after the company said it has entered into agreements with certain (LOL) institutional investors to buy 4.6 million common shares at $2.40 a share in a registered direct offering.
The biotechnology company said it expects to see proceeds of $11 million , before payment of commissions and expenses.
In a concurrent private placement, for each share bought by an investor, that investor will receive an unregistered warrant to purchase one share. The warrants have an exercise price of $2.53 a share, and are exercisable for a five-year period beginning six months from the date of issuance.
Aditxt said it plans to use the proceeds from this offering to fund a $6.5 million loan to a biopharmaceutical company commercializing Covid-19 antiviral oral therapy, and for general corporate and working capital purposes, including the purchase of fixed assets.
Aditxt Inc. shares were down 30% to $2.14 after the company said it has entered into agreements with certain (LOL) institutional investors to buy 4.6 million common shares at $2.40 a share in a registered direct offering.
The biotechnology company said it expects to see proceeds of $11 million , before payment of commissions and expenses.
In a concurrent private placement, for each share bought by an investor, that investor will receive an unregistered warrant to purchase one share. The warrants have an exercise price of $2.53 a share, and are exercisable for a five-year period beginning six months from the date of issuance.
Aditxt said it plans to use the proceeds from this offering to fund a $6.5 million loan to a biopharmaceutical company commercializing Covid-19 antiviral oral therapy, and for general corporate and working capital purposes, including the purchase of fixed assets.
Recent ADTX News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2026 08:20:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/01/2026 08:35:47 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/23/2026 08:30:42 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/22/2026 04:15:21 AM
- Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics’ RPPA Platform for T-DXd (Enhertu®) Therapy in Metastatic Breast Cancer Patients • Business Wire • 04/20/2026 12:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/14/2026 12:00:13 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 04/11/2026 01:49:19 AM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 04/07/2026 08:02:58 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/03/2026 08:37:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 01:13:36 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2026 08:35:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/30/2026 12:00:37 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 03/27/2026 09:02:12 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/24/2026 09:21:36 PM
- Aditxt Subsidiary Ignite Proteomics Appoints Public Company Veteran Jeff Busch as Chief Executive Officer • Business Wire • 03/19/2026 12:15:00 PM
- Aditxt Acquires Ignite Proteomics to Expand Precision Oncology Capabilities • IH Market News • 03/13/2026 03:36:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/13/2026 12:35:24 PM
- Aditxt Acquires Ignite Proteomics to Address a Critical Challenge in Cancer Care: Optimizing Therapy Selection • Business Wire • 03/13/2026 12:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:30:35 PM
- Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-8 Reverse Stock Split Effective at the Open of Trading on March 9, 2026 • Business Wire • 03/05/2026 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2026 10:03:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2026 09:23:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/28/2026 01:00:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2025 10:00:02 PM
